毛发中乙基葡萄糖醛酸苷检测发现拟诊非酒精性脂肪性肝病患者中存在高比例有害饮酒
这项前瞻性观察研究纳入184例连续患者,用毛发和尿液乙基葡萄糖醛酸苷(hEtG、uEtG)检测饮酒,并与AUDIT-C、CDT、MCV、GGT、ANI比较。结果显示,拟诊NAFLD、ALD或MAFLD患者中反复中至过量饮酒的比例分别为28.6%、28.5%、25.0%;hEtG检测的AUC为0.927。作者认为AUDIT-C、uEtG和hEtG应筛查脂肪性肝病患者的饮酒情况。
要点
- 拟诊NAFLD患者中28.6%存在反复中至过量饮酒,MAFLD患者中为25.0%。
- hEtG检测反复中至过量饮酒的AUC为0.927,优于AUDIT-C、uEtG和ANI。
- CDT、MCV和GGT等间接标志物不可靠。
核心结论
- 拟诊NAFLD患者中28.6%、MAFLD患者中25.0%存在酒精相关肝损伤风险。
- AUDIT-C、uEtG和hEtG应筛查脂肪性肝病患者的饮酒情况。
研究设计与样本
- 前瞻性观察研究,共纳入184例连续患者。
- 饮酒评估采用毛发乙基葡萄糖醛酸苷(hEtG)、尿液乙基葡萄糖醛酸苷(uEtG),并与AUDIT-C、CDT、MCV、GGT、ANI比较。
- 根据反复中量(≥10 g且<60 g乙醇/天)和过量(≥60 g乙醇/天)饮酒重新评估NAFLD和ALD患者的临床特征,并按MAFLD标准回顾性重新分类。
主要发现
- 拟诊NAFLD、ALD或MAFLD患者中反复中至过量饮酒的比例分别为28.6%、28.5%、25.0%。
- ANI、AUDIT-C、uEtG、hEtG检测反复中至过量饮酒的AUC分别为0.628、0.733、0.754、0.927。
- CDT、MCV和GGT等间接标志物不可靠。
- 反复中量或过量饮酒者男性显著更多、BMI显著更低、2型糖尿病或糖耐量受损显著更少。
关键数值与推荐
- 反复中量饮酒定义为≥10 g且<60 g乙醇/天,过量饮酒定义为≥60 g乙醇/天。
- hEtG检测反复中至过量饮酒的AUC为0.927。
- uEtG检测反复中至过量饮酒的AUC为0.754。
- AUDIT-C检测反复中至过量饮酒的AUC为0.733。
- ANI检测反复中至过量饮酒的AUC为0.628。
临床怎么用
- 作者认为AUDIT-C、uEtG和hEtG应筛查脂肪性肝病患者的饮酒情况。
- 作者认为毛发和尿液乙基葡萄糖醛酸苷检测应整合到脂肪性肝病患者的常规诊断流程中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) cannot reliably be distinguished by routine diagnostics, and the role of alcohol consumption in metabolic dysfunction-associated fatty liver disease (MAFLD) remains unclear. We investigated alcohol consumption in patients with presumed NAFLD and ALD using novel objective alcohol markers. METHODS: In total, 184 consecutive patients were included in this prospective observational study. Alcohol intake was assessed by ethylglucuronide in hair (hEtG) and urine (uEtG); the utility of these measures for alcohol detection was compared to Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), carbohydrate deficient transferrin (CDT), mean corpuscular volume (MCV), gamma-glutamyltransferase (GGT), and ALD/NAFLD index (ANI). Clinical characteristics of patients with NAFLD and ALD were re-assessed after reclassification based on repeated moderate (≥10 g <60 g EtOH/day) and excessive (≥60 g EtOH/day) alcohol consumption, and patients were retrospectively reclassified based on MAFLD criteria. RESULTS: Repeated moderate to excessive alcohol consumption was detected in 28.6%, 28.5%, and 25.0% of patients with presumed NAFLD, ALD or MAFLD, respectively. ANI score, AUDIT-C, uEtG, and hEtG showed AUCs of 0.628, 0.733, 0.754, and 0.927 for the detection of repeated moderate to excessive alcohol consumption, respectively. The indirect markers CDT, MCV and GGT were not reliable. Patients with repeated moderate or excessive alcohol consumption were significantly more often male, had a significantly lower BMI, and suffered significantly less often from type 2 diabetes or impaired glucose tolerance. CONCLUSIONS: In total, 28.6% of patients with presumed NAFLD, and 25.0% with MAFLD are at risk of alcohol-related liver damage. AUDIT-C, uEtG and hEtG should be used to screen for alcohol consumption in patients with fatty liver disease. LAY SUMMARY: Fatty liver disease can be caused by metabolic factors and/or alcohol consumption. The diagnosis of non-alcoholic fatty liver disease (NAFLD) is based on the exclusion of harmful alcohol consumption, while metabolic dysfunction-associated fatty liver disease (MAFLD), which has been proposed as a new name for NAFLD, is based on the presence of metabolic comorbidities and allows for alcohol consumption. Herein, we show that up to 29% of patients diagnosed with NAFLD and 25% with MAFLD are at risk of alcohol-related liver damage. We show that ethyl glucuronide (a metabolite of alcohol) in the hair and urine can accurately detect potentially harmful alcohol consumption in these patients - as such, these tests should be integrated into routine diagnostic work-up for patients with fatty liver disease.
引用
- Staufer K, Huber-Schönauer U, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022. PMID: 35605744. doi:10.1016/j.jhep.2022.04.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。